keyword
MENU ▼
Read by QxMD icon Read
search

Type 2 diabetes and basal insulin

keyword
https://www.readbyqxmd.com/read/28938142/insulin-regimens-and-glycemic-control-in-different-parts-of-europe-over-4years-after-starting-insulin-in-people-with-type-2-diabetes-data-from-the-credit-non-interventional-study
#1
Lawrence Blonde, Michel Marre, Maya Vincent, Sandrine Brette, Valerie Pilorget, Nicholas Danchin, Giacomo Vespasiani, Philip Home
AIMS: A number of insulin regimens are used in type 2 diabetes. This analysis aims to better understand the evolution of insulin therapy in different regions of Europe. METHODS: Data from people starting any insulin were collected in eastern Europe (EEur: Croatia, Russia, Ukraine), northern Europe (NEur: Finland, Germany, UK) and southern Europe (SEur: France, Italy, Portugal, Spain). Retrospective data on starting insulin and prospective follow-up data were extracted from clinical records...
August 31, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28927285/impact-of-a-basal-bolus-insulin-regimen-on-metabolic-control-and-risk-of-hypoglycemia-in-patients-with-diabetes-undergoing-peritoneal-dialysis
#2
Ana María Gómez, Santiago Vallejo, Freddy Ardila, Oscar M Muñoz, Álvaro J Ruiz, Mauricio Sanabria, Alfonso Bunch, Elly Morros, Laura Kattah, Maira García-Jaramillo, Fabián León-Vargas
INTRODUCTION: Clinical interventional studies in diabetes mellitus usually exclude patients undergoing peritoneal dialysis (PD). This study evaluates the impact of an educational program and a basal-bolus insulin regimen on the blood glucose level control and risk of hypoglycemia in this population. METHODS: A before-and-after study was conducted in type 1 and type 2 DM patients undergoing PD at the Renal Therapy Services (RTS) clinic network, Bogota, Colombia. An intervention was instituted consisting of a three-month educational program and a basal-bolus detemir (Levemir, NovoNordisk) and aspart (Novorapid, NovoNordisk) insulin regimen...
September 1, 2017: Journal of Diabetes Science and Technology
https://www.readbyqxmd.com/read/28921900/efficacy-and-safety-of-switching-from-basal-insulin-to-once-daily-insulin-idegasp-in-japanese-patients-with-inadequately-controlled-type-2-diabetes-a-4-week-randomized-open-label-treat-to-target-study
#3
Yoshio Nagai, Ami Nishine, Eriko Hashimoto, Taiga Nakayama, Yosuke Sasaki, Mariko Murakami, Satoshi Ishii, Hiroyuki Kato, Yasushi Tanaka
AIMS/INTRODUCTION: A prospective, 4-week, single-center, randomized, open-label, parallel-group, treat-to-target study was performed to develop an algorithm for safe and effective switching from basal insulin to once-daily insulin degludec/insulin aspart (IDegAsp) in patients with inadequately controlled type 2 diabetes. MATERIALS AND METHODS: Patients were randomly assigned to continue their current basal insulin therapy (n=10) or to switch to IDegAsp on a 1: 1 unit basis (n=10)...
September 16, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/28918342/the-potential-effect-of-ultra-long-insulin-degludec-on-glycemic-variability
#4
REVIEW
M Rodacki, R M Carvalho, L Zajdenverg
Despite the therapeutic advances in the treatment of diabetes, metabolic control instability due to glycemic variability (GV) is frequently observed in patients with diabetes on intensive insulin therapy and is associated with hyperglycemic peaks and hypoglycemic episodes. Hyperglycemia associated with GV has been implicated in the development of chronic complications due to its pro-oxidative consequences. On the other hand, hypoglycemia can be associated with increased cardiovascular risk secondarily to adrenergic activation...
June 30, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28904527/cost-effectiveness-of-vildagliptin-versus-glimepiride-as-add-on-treatment-to-metformin-for-the-treatment-of-diabetes-mellitus-type-2-patients-in-greece
#5
Hara Kousoulakou, Magdalini Hatzikou, Varvara Baroutsou, John Yfantopoulos
OBJECTIVES: This study was designed to assess the cost-effectiveness of vildagliptin versus glimepiride as add-on to metformin in the management of type 2 diabetes mellitus (T2DM) patients in the Greek healthcare setting. METHODS: A cost-effectiveness model was designed, using MS Excel, to compare two treatment strategies. Strategy 1 consisted of first-line metformin, followed by metformin + vildagliptin in second-line, while strategy 2 consisted of first line metformin, followed by metformin + glimepiride in second line...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28895642/initiation-of-basal-insulin-analog-treatment-for-type-2-diabetes-and-reasons-behind-patients-treatment-persistence-behavior-real-world-data-from-germany
#6
Elisabeth Moennig, Magaly Perez-Nieves, Irene Hadjiyianni, Dachuang Cao, Jasmina Ivanova, Ralf Klask
Background Poor treatment persistence can affect the real-world effectiveness of insulin therapy. A cross-sectional online survey in 942 patients with type 2 diabetes from 7 different countries evaluated patient experience when initiating basal insulin and the reasons behind insulin persistence patterns. Here, we report the quantitative results for the subset of patients from Germany. Methods Adults with type 2 diabetes who had initiated basal insulin during the last 3-24 months, identified from market-research panels, participated in the survey...
September 11, 2017: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/28892956/short-term-efficacy-and-safety-of-insulin-glargine-in-type-2-diabetes-inadequately-controlled-with-single-or-two-oral-agents-a-prospective-open-label-study
#7
Ajay Aggarwal, Roopak Wadhwa
INTRODUCTION: Basal insulin is among the second line treatment options for Type 2 Diabetes Mellitus (T2DM). Efficacy and safety of basal insulin in patients of T2DM, uncontrolled with Oral Antidiabetic Agents (OAAs) remains understudied in the Indian setting. AIM: To assess the efficacy and safety of insulin glargine in patients with T2DM who have uncontrolled glycaemic levels despite single or two OAAs therapy. MATERIALS AND METHODS: In this prospective, open label study, T2DM patients above 40 years of age, having inadequate glycaemic control [Glycosylated Haemoglobin (HbA1c) above 8% and/or fasting glucose level of 140 mg/dl and above] with single or two OAAs over three consecutive months were included...
July 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28888986/pde-5-inhibitor-improves-insulin-sensitivity-by-enhancing-mitochondrial-function-in-adipocytes
#8
Hea Min Yu, Hyo Kyun Chung, Koon Soon Kim, Jae Min Lee, Jun Hwa Hong, Kang Seo Park
Adipocytes are involved in many metabolic disorders. It was recently reported that phosphodiesterase type 5 (PDE5) is expressed in human adipose tissue. In addition, PDE5 inhibitors have been shown to improve insulin sensitivity in humans. However, the mechanism underlying the role of PDE5 inhibitors as an insulin sensitizer remains largely unknown. The present study was undertaken to investigate the role of the PDE5 inhibitor udenafil in insulin signaling in adipocytes and whether this is mediated through the regulation of mitochondrial function...
September 6, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28884311/improved-glycemic-control-achieved-by-switching-to-insulin-degludec-in-insulin-treated-patients-with-type-2-diabetes-in-a-real-world-setting-a-non-interventional-retrospective-cohort-study
#9
Cheli Melzer Cohen, Brian Larsen Thorsted, Michael Lyng Wolden, Gabriel Chodick, Avraham Karasik
INTRODUCTION: Retrospective cohort study evaluating the clinical effectiveness of insulin degludec (IDeg) in insulin-treated patients with type 2 diabetes switching from other insulins to IDeg in a real-world setting. METHODS: Data were drawn from the Maccabi Health Management Organization in Israel and included patients treated with IDeg between 1 September 2014 and 29 February 2016. Main inclusion criteria were age ≥18 years, diagnosis of type 2 diabetes, and treated with insulin for at least 1 year prior to IDeg initiation...
September 7, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28875766/postprandial-glucose-and-healthcare-resource-use-a-cross-sectional-survey-of-adults-with-diabetes-treated-with-basal-bolus-insulin
#10
Kathryn M Pfeiffer, Anna Sandberg, Annie Nikolajsen, Meryl Brod
AIMS: Postprandial glucose (PPG) control is a well-known challenge for diabetes management, yet there is limited research on how PPG affects healthcare resource utilization. This study investigated the association between PPG levels and healthcare resource utilization among adults with diabetes treated with basal-bolus insulin. METHODS: A web-based, cross-sectional survey (n = 940) of adults with type 1 or type 2 diabetes and treated with basal and bolus insulins was conducted in Italy, the United Kingdom, and the United States...
September 6, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28875722/diabetes-injectable-therapy-type-2-diabetes-management-in-danish-practice
#11
Daniel Sterzi, Sébastien Auziere, Marie Markert Jensen, Sandra Lopes
Most diabetes care is done by GPs in Denmark. This study aimed to identify the barriers for GPs to initiate injectable therapies and reasons for referral to specialists. The web-interview conducted included 85 GPs, and 30 specialists experienced in type 2 diabetes (T2D). GPs felt more comfortable with initiating the 1(st) injectable therapy (defined as a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or basal insulin) than the 2(nd) (defined as adding a basal insulin in patients treated with a GLP-1 RA (± OADs), or adding either a GLP-1 RA or a bolus insulin in patients treated with basal insulin (± OADs)...
September 6, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28860191/isoform-selective-inhibitor-of-histone-deacetylase-3-hdac3-limits-pancreatic-islet-infiltration-and-protects-female-nonobese-diabetic-mice-from-diabetes
#12
Ercument Dirice, Raymond Ng, Rachael Martinez, Jiang Hu, Florence F Wagner, Edward B Holson, Bridget K Wagner, Rohit N Kulkarni
Preservation of insulin-secreting β-cells is an important goal for therapies aimed at restoring normoglycemia in patients with diabetes. One approach, the inhibition of histone deacetylases (HDACs), has been reported to suppress pancreatic islet inflammation and β-cell apoptosis in vitro. In this report, we demonstrate the efficacy of HDAC inhibitors (HDACi) in vivo. We show that daily administration of BRD3308, an isoform-selective HDAC3 inhibitor, for 2 weeks to female nonobese diabetic (NOD) mice, beginning at 3 weeks of age, followed by twice-weekly injections until age 25 weeks, protects the animals from diabetes...
August 31, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28842165/chronic-kidney-disease-basal-insulin-glargine-and-health-outcomes-in-people-with-dysglycemia-the-origin-study
#13
Vasilios Papademetriou, Eric S Nylen, Michael Doumas, Jeff Probstfield, Johannes F E Mann, Richard E Gilbert, Hertzel C Gerstein
BACKGROUND: Early stages of chronic kidney disease are associated with an increased cardiovascular risk in patients with established type 2 diabetes and macrovascular disease. The role of early stages of chronic kidney disease on macrovascular outcomes in prediabetes and early type two diabetes mellitus is not known. In the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, the introduction of insulin had no effect on cardiovascular outcomes compared to standard therapy...
August 22, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28837278/-therapeutic-options-for-a-type-2-diabetic-patient-not-well-controlled-with-metformin-plus-basal-insulin
#14
André J Scheen, Nicolas Paquot
In a patient with type 2 diabetes not well controlled with a basal insulin - metformin combination, several therapeutic options may be considered: intensifying insulin therapy with different schemes (appropriate titration using a more favourable basal insulin analogue, adding one, two or three rapid-acting insulin analogues, shift to two or three premix insulin injections), adding a dipeptidyl peptidase-4 inhibitor (gliptin) or an inhibitor of sodium-glucose cotransporters type 2 (gliflozin), or combining a glucagon-like peptide-1 receptor agonist with basal insulin...
August 23, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28836974/insulin-prices-availability-and-affordability-a-cross-sectional-survey-of-pharmacies-in-hubei-province-china
#15
Chenxi Liu, Xinping Zhang, Chaojie Liu, Margaret Ewen, Zinan Zhang, Guoqin Liu
BACKGROUND: Poor access to affordable insulin results in serious and needless complications and premature deaths for those with diabetes who need this essential medicine. To help address this issue, we assessed insulin availability, prices, affordability and price components in Hubei Province as China has the heaviest burden of diabetes globally. METHODS: In 2016, insulin availability and price data was collected in the capital and five other cities. A total of 30 public sector outlets (hospitals and primary care institutions) and 30 private pharmacies were sampled, using an adaptation of the World Health Organization/Health Action International methodology, Data was collected for all human and analogue insulins in stock, then analyzed by type (prandial, basal or pre-mixed) and duration of action...
August 24, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28836861/adding-prandial-glp-1-receptor-agonists-to-basal-insulin-a-promising-option-for-type-2-diabetes-therapy
#16
Ronald M Goldenberg, Lori Berard
BACKGROUND: Diabetes mellitus is a serious and increasingly prevalent condition in Canada and around the world. Treatment strategies have become increasingly complex, with a widening array of pharmacological agents available for glycemic management in type 2 diabetes mellitus (T2DM). New therapies that act in concert with available basal insulins may represent alternatives to basal insulin intensification with prandial or premixed insulin. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have recently shown promise as useful additions to basal insulin, with significant reductions in glycated hemoglobin and potentially beneficial effects on body weight...
August 24, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28835758/association-of-insulinoma-and-type-2-diabetes-mellitus
#17
Hassan Ouleghzal, Tarik Ziadi, Mohammed Menfaa, Soumia Safi
The association of diabetes mellitus and insulinoma is unusual. We are reporting the case of a 58 years old patient having diabetes mellitus type 2 for several years. This patient was well balanced with oral anti-diabetic treatment. However, the diagnosis of insulinoma was discussed due to recent episodes of hypoglycemia that persisted even after stopping the treatment. Abdominal CT allowed the topographic diagnosis. The patient underwent a caudal pancreatectomy. Furthermore, the postoperative period shows that the diabetes mellitus requires the oral anti-diabetic treatment and basal insulin have to be stable...
January 2017: International Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28832099/consensus-on-insulin-dose-modification-during-fasting-in-type-2-diabetes
#18
A G Unnikrishnan, Sailesh Lodha, S K Sharma
INTRODUCTION: Fasting for patients with type 2 diabetes mellitus (T2DM) carries a risk of an assortment of complications. The decision of T2DM patient to fast should be made after sufficient discussion with physician regarding the risks involved. The current consensus is developed to help physicians manage T2DM patients during fasting. OBJECTIVE: To provide simple and easily implementable guidelines on insulin dose modification during fasting in T2DM patients. METHODS: The expert group committee discussed and proposed six recommendations for the use of insulin regimens during fasting...
March 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/28822051/new-basal-insulins-a-clinical-perspective-of-their-use-in-the-treatment-of-type-2-diabetes-and-novel-treatment-options-beyond-basal-insulin
#19
REVIEW
Patrick F Frias, Juan Pablo Frias
PURPOSE OF REVIEW: The purpose of this review was to review advances in basal insulin formulations and new treatment options for patients with type 2 diabetes not achieving glycemic targets despite optimized basal insulin therapy. RECENT FINDINGS: Advances in basal insulin formulations have resulted in products with increasingly favorable pharmacokinetic and pharmacodynamic properties, including flatter, peakless action profiles, less inter- and intra-patient variability, and longer duration of activity...
August 18, 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28817342/hypoglycemia-risk-related-to-double-dose-is-markedly-reduced-with-basal-insulin-peglispro-versus-insulin-glargine-in-patients-with-type-2-diabetes-mellitus-in-a-randomized-trial-imagine-8
#20
Cynthia Harris, Thomas Forst, Tim Heise, Leona Plum-Mörschel, Elaine Watkins, Qianyi Zhang, Ludi Fan, Parag Garhyan, Niels Porksen
BACKGROUND: Basal insulin peglispro (BIL) has a peripheral-to-hepatic distribution of action that resembles endogenous insulin and a prolonged duration of action with a flat pharmacokinetic/pharmacodynamic profile at steady state, characteristics that tend to reduce hypoglycemia risk compared to insulin glargine (GL). The primary objective was to demonstrate that clinically significant hypoglycemia (blood glucose ≤54 mg/dL [3.0 mmol/L] or symptoms of severe hypoglycemia) occurred less frequently within 84 h after a double dose (DD) of BIL than a DD of GL...
August 2017: Diabetes Technology & Therapeutics
keyword
keyword
32685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"